The U. S. Food and Drug Administration approved ofatumumab (Arzerra Injection, for intravenous infusion; GlaxoSmithKline) in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate. More >
Welcome to Focus on CLL
The FocusOnCLL.org website is designed to provide helpful information and resources to patients, caregivers, physicians, and others affected by chronic lymphocytic leukemia (CLL).
We invite you to browse the site to learn more about CLL.
Getting the Facts
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are B-cell malignancies. CLL and SLL are essentially the same disease, with slightly different manifestations. CLL tends to be an indolent (slow-growing) cancer. However, over time, it can progress to a more aggressive type of lymphoma. Approximately 15,000 new cases of CLL are diagnosed annually.
Recent research into chronic lymphocytic leukemia has led to significant advancements in the understanding of the disease. Research continues on multiple fronts to develop better treatments for patients. We hope you will find the information presented here useful in understanding your disease and discussing it with your healthcare team.